Nevin Hande Dikel, Erhan Yumuşak, Nesrin Büyüktortop Gökçınar, Turkey

Purpose:
To compare the long-term efficacy and safety results of intravitreal ranibizumab (RAN), dexamethasone intravitreal implant (DEX), and intravitreal triamcinolone acetonide (IVTA) injections in macular edema due to branch retinal vein occlusion (BRVO).

Methods:
In this retrospective study one eye each of 43 patients who were treated with intravitreal injections for macular edema secondary to BRVO was recruited into one of the study groups: RAN group (n = 17), DEX group (n = 16), and IVTA group (n = 10). All patients were followed-up for 12 months. Best-corrected visual acuity (BCVA), central macular thickness (CMT), subfoveal choroidal thickness (SFCT), and intraocular pressure (IOP) at month 1, 3, 6, and 12 were compared with the baseline.

Results:
The BCVA increased significantly in the RAN and DEX groups at all visits (all p<0.05). BCVA increase in the IVTA group was significant only at month 1, and 6. CMT decreased significantly in all groups at the end of one-year of follow-up (p=0,007; p=0,001; p=0,044, respectively). SFCT significantly decreased in all groups at month 1 (all p<0.05). IOP significantly increased in none, 18.8%, 30% of the patients in the RAN, DEX and IVTA groups, respectively. Cataract surgery was required in none, 8.3% and 50% of the phakic patients in the RAN, DEX and IVTA groups, respectively.

Conclusions:
BCVA increase was more prominent in both of the RAN and DEX groups than in the IVTA group. DEX may decrease the injection burden, however, ranibizumab may be a safer choice.

Contact Details:
Nevin Hande Dikel
Karaman State Hospital
Karaman
Turkey
Cell Phone : +905354008898
Work Phone : +903382263000
Email : hande_dikel@hotmail.com